Published in Proc Natl Acad Sci U S A on March 13, 2001
Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci U S A (2008) 1.43
Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40
Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J Am Chem Soc (2006) 1.39
Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc Natl Acad Sci U S A (2005) 1.34
Multi-component one-pot synthesis of the tumor-associated carbohydrate antigen Globo-H based on preactivation of thioglycosyl donors. J Org Chem (2007) 1.27
Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc Natl Acad Sci U S A (2004) 1.27
Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia (2006) 1.23
Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res (2011) 1.15
Design and synthesis of potent Quillaja saponin vaccine adjuvants. J Am Chem Soc (2010) 1.12
A facile method for oxidation of primary alcohols to carboxylic acids and its application in glycosaminoglycan syntheses. Chemistry (2006) 1.11
Recent Departures in the Synthesis of Peptides and Glycopeptides. Tetrahedron (2009) 1.07
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci U S A (2013) 1.07
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines (2011) 1.06
Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol (2013) 1.04
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience. Expert Rev Vaccines (2009) 1.01
On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc Natl Acad Sci U S A (2002) 0.99
Recent Development in Carbohydrate Based Anti-cancer Vaccines. J Carbohydr Chem (2012) 0.98
Synthetically defined glycoprotein vaccines: current status and future directions. Chem Sci (2013) 0.97
A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic. J Am Chem Soc (2013) 0.96
'Multicopy multivalent' glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines. J Am Chem Soc (2013) 0.94
Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains. J Am Chem Soc (2009) 0.93
Clustered carbohydrates in synthetic vaccines. Chem Soc Rev (2012) 0.91
Immunization of fucose-containing polysaccharides from Reishi mushroom induces antibodies to tumor-associated Globo H-series epitopes. Proc Natl Acad Sci U S A (2013) 0.90
Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen. Neoplasia (2009) 0.87
A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis. J Am Chem Soc (2009) 0.87
Protein modifications as potential biomarkers in breast cancer. Biomark Insights (2009) 0.87
A practical total synthesis of globo-H for use in anticancer vaccines. J Org Chem (2009) 0.85
Chemoenzymatic Syntheses of Tumor-Associated Carbohydrate Antigen Globo-H and Stage-Specific Embryonic Antigen 4. Adv Synth Catal (2008) 0.83
Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother (2011) 0.82
The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration. Br J Cancer (2014) 0.81
Metabolic engineering of Agrobacterium sp. strain ATCC 31749 for production of an alpha-Gal epitope. Microb Cell Fact (2010) 0.81
Triterpenoid saponins from the roots of Acanthophyllum gypsophiloides Regel. Beilstein J Org Chem (2012) 0.80
Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J (2012) 0.80
"Biologic" level structures through chemistry: A total synthesis of a unimolecular pentavalent MUCI glycopeptide construct. Tetrahedron Lett (2009) 0.79
Automated assembly of oligosaccharides containing multiple cis-glycosidic linkages. Nat Commun (2016) 0.79
Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging. Mol Pharm (2013) 0.77
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission. Cancers (Basel) (2016) 0.77
Novel therapeutic approaches for small cell lung cancer: the future has arrived. Curr Probl Cancer (2012) 0.77
Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents. Front Oncol (2016) 0.76
A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity. Chem Sci (2015) 0.76
Chemical Synthesis of the Tumor-Associated Globo H Antigen. RSC Adv (2015) 0.76
Antibody Repertoire Profiling with Mimotope Arrays. Hum Vaccin Immunother (2016) 0.75
Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice. J Immunol Res (2015) 0.75
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A (1996) 2.52
Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol (1991) 2.44
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst (1993) 1.73
Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem (1984) 1.70
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A (1999) 1.63
Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res (1983) 1.60
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res (1994) 1.32
Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst (1981) 1.30
Optimal sample size for a series of pilot trials of new agents. Biometrics (1996) 1.28
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine (1994) 1.28
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res (1999) 1.20
Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res (1996) 1.12
Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother (1997) 1.07
Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother (1997) 1.07
A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj J (1998) 1.05
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc Natl Acad Sci U S A (2000) 1.02
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother (1996) 1.00
Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother (1997) 0.84
Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1. Cancer Immunol Immunother (2000) 0.82
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Raf-1 activates MAP kinase-kinase. Nature (1992) 7.05
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature (2001) 4.73
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol (2000) 4.33
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Leptomeningeal metastases in the MRI era. Neurology (2010) 3.48
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A (1997) 3.23
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Infant botulism. Epidemiological, clinical, and laboratory aspects. JAMA (1977) 3.05
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
AIDS: an international perspective. Science (1988) 2.84
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci (1994) 2.75
Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl Acad Sci U S A (1989) 2.73
Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A (1995) 2.70
Intestinal infection and toxin production by Clostridium botulinum as one cause of sudden infant death syndrome. Lancet (1978) 2.60
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 2.46
Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology (2008) 2.44
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Prevention of chronic hepatitis B virus infection from mothers to infants in the United States. Pediatrics (1983) 2.41
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25
Global surveillance and forecasting of AIDS. Bull World Health Organ (1989) 2.17
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
The international epidemiology of AIDS. Sci Am (1988) 2.08
Secondary neoplasms of the breast: a survey of the 20th Century. Cancer (2001) 2.07
Evidence for secular trends in children's physical activity behaviour. Br J Sports Med (2005) 2.07
Reciprocal control of RNA-binding and aconitase activity in the regulation of the iron-responsive element binding protein: role of the iron-sulfur cluster. Proc Natl Acad Sci U S A (1992) 2.06
High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) (2010) 2.02
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
A new venous prosthesis. Surgery (1972) 2.01
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res (2000) 1.99
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98
Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res (2000) 1.97
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest (1993) 1.94
An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol (2001) 1.93
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res (2001) 1.87
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia (2008) 1.84
Production of mucoid exopolysaccharide during development of Pseudomonas aeruginosa biofilms. Infect Immun (1993) 1.83
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Filter paper disc method of collecting whole blood for serologic studies in children. Am J Epidemiol (1966) 1.82
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr (1996) 1.81
Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2. Structure, function, and post-translational regulation. J Biol Chem (1994) 1.79
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Heterotransplantation of human malignant tumors in "nude" thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J Natl Cancer Inst (1974) 1.74
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol (1998) 1.74
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst (1996) 1.70
The Norton-Simon hypothesis revisited. Cancer Treat Rep (1986) 1.70
Identification of Nore1 as a potential Ras effector. J Biol Chem (1998) 1.69
Honey and other environmental risk factors for infant botulism. J Pediatr (1979) 1.68
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Interleukin 1 beta is localized in the cytoplasmic ground substance but is largely absent from the Golgi apparatus and plasma membranes of stimulated human monocytes. J Exp Med (1988) 1.66
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol (2001) 1.66
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol (1991) 1.65
Stroke in patients with cancer: incidence and etiology. Neurology (2004) 1.65
Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy. Cancer (1978) 1.64
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A (1999) 1.63